[
  {
    "title": "皓元医药(688131.SH)：资产重组事项获证监会注册批复",
    "href": "http://stock.jrj.com.cn/2022/12/05182937189500.shtml",
    "datetime": "2022-12-05 18:29:44",
    "code": "688131"
  },
  {
    "title": "皓元医药(688131.SH)：资产重组事项获科创板并购重组委审议通过",
    "href": "http://stock.jrj.com.cn/2022/11/08200537121741.shtml",
    "datetime": "2022-11-08 20:05:22",
    "code": "688131"
  },
  {
    "title": "皓元医药(688131.SH)：资产重组事项将于11月8日上会",
    "href": "http://stock.jrj.com.cn/2022/11/01192237104292.shtml",
    "datetime": "2022-11-01 19:22:21",
    "code": "688131"
  },
  {
    "title": "皓元医药收购资产暂缓审议：标的资产业绩预测需要再落实 上半年基金上演减持潮",
    "href": "http://stock.jrj.com.cn/2022/09/16161137000489.shtml",
    "datetime": "2022-09-16 16:11:31",
    "code": "688131"
  },
  {
    "title": "皓元医药(688131.SH)：资产重组事项获科创板并购重组委暂缓审议",
    "href": "http://stock.jrj.com.cn/2022/09/15215136998628.shtml",
    "datetime": "2022-09-15 21:51:52",
    "code": "688131"
  },
  {
    "title": "皓元医药应收款激增1.8倍疑业绩虚增 溢价6倍收购资产谋变或需12年回本",
    "href": "http://stock.jrj.com.cn/2022/09/14100936993279.shtml",
    "datetime": "2022-09-14 10:09:30",
    "code": "688131"
  },
  {
    "title": "皓元医药(688131.SH)：资产重组事项将于9月15日上会",
    "href": "http://stock.jrj.com.cn/2022/09/08082636982023.shtml",
    "datetime": "2022-09-08 08:26:58",
    "code": "688131"
  },
  {
    "title": "皓元医药(688131.SH)：拟将“安徽皓元年产121.095吨医药原料药及中间体建设项目(一期)”延期",
    "href": "http://stock.jrj.com.cn/2022/08/31201936959547.shtml",
    "datetime": "2022-08-31 20:19:20",
    "code": "688131"
  },
  {
    "title": "皓元医药披露2022年半年报 实现营收6.21亿元",
    "href": "http://stock.jrj.com.cn/2022/08/26134036940224.shtml",
    "datetime": "2022-08-26 13:40:38",
    "code": "688131"
  },
  {
    "title": "皓元医药(688131)：使用部分超募资金永久补充流动资金",
    "href": "http://stock.jrj.com.cn/2022/08/26090336939058.shtml",
    "datetime": "2022-08-26 09:03:12",
    "code": "688131"
  },
  {
    "title": "皓元医药(688131.SH)：上半年净利润增22.51%至1.16亿元",
    "href": "http://stock.jrj.com.cn/2022/08/25214736937565.shtml",
    "datetime": "2022-08-25 21:47:06",
    "code": "688131"
  },
  {
    "title": "皓元医药(688131.SH)：拟使用不超3亿元暂时闲置募集资金进行现金管理",
    "href": "http://stock.jrj.com.cn/2022/08/04193836871253.shtml",
    "datetime": "2022-08-04 19:38:22",
    "code": "688131"
  },
  {
    "title": "皓元医药(688131.SH)：已向上交所申请恢复审核公司资产重组事项",
    "href": "http://stock.jrj.com.cn/2022/08/03183236867572.shtml",
    "datetime": "2022-08-03 18:32:03",
    "code": "688131"
  },
  {
    "title": "皓元医药发股购买资产并募集配套资金事宜遭中止审核",
    "href": "http://stock.jrj.com.cn/2022/08/01112236858459.shtml",
    "datetime": "2022-08-01 11:22:38",
    "code": "688131"
  },
  {
    "title": "皓元医药(688131.SH)：上交所中止对公司资产重组事项的审查",
    "href": "http://stock.jrj.com.cn/2022/07/31162236856576.shtml",
    "datetime": "2022-07-31 16:22:24",
    "code": "688131"
  },
  {
    "title": "皓元医药(688131)：股东减持股份数量过半暨减持进展",
    "href": "http://stock.jrj.com.cn/2022/07/25093936838954.shtml",
    "datetime": "2022-07-25 09:39:13",
    "code": "688131"
  },
  {
    "title": "皓元医药(688131.SH)：减持数过半 真金投资累计减持2.52%股份",
    "href": "http://stock.jrj.com.cn/2022/07/22185236836641.shtml",
    "datetime": "2022-07-22 18:52:41",
    "code": "688131"
  },
  {
    "title": "皓元医药(688131)：股东减持股份数量过半暨减持进展",
    "href": "http://stock.jrj.com.cn/2022/07/20094236827548.shtml",
    "datetime": "2022-07-20 09:42:06",
    "code": "688131"
  },
  {
    "title": "皓元医药(688131.SH)：三家股东已合计减持2.3732%的股份",
    "href": "http://stock.jrj.com.cn/2022/07/19194836826149.shtml",
    "datetime": "2022-07-19 19:48:53",
    "code": "688131"
  },
  {
    "title": "皓元医药(688131.SH)：发行股份购买资产相关申请获上交所受理",
    "href": "http://stock.jrj.com.cn/2022/07/15143036815665.shtml",
    "datetime": "2022-07-15 14:30:37",
    "code": "688131"
  },
  {
    "title": "皓元医药(688131.SH)：真金投资近期累计减持1.9695%股份 持股降至5%以下",
    "href": "http://stock.jrj.com.cn/2022/07/08194736795618.shtml",
    "datetime": "2022-07-08 19:47:38",
    "code": "688131"
  },
  {
    "title": "皓元医药(688131.SH)：虎跃永沃拟减持不超1.9928%股份",
    "href": "http://stock.jrj.com.cn/2022/07/08191636795506.shtml",
    "datetime": "2022-07-08 19:16:54",
    "code": "688131"
  },
  {
    "title": "皓元医药(688131)：持股5%以上股东减持比例超过1%",
    "href": "http://stock.jrj.com.cn/2022/07/06090036785883.shtml",
    "datetime": "2022-07-06 09:00:46",
    "code": "688131"
  },
  {
    "title": "皓元医药(688131.SH)：景嘉创业以大宗交易减持0.7590%的股份",
    "href": "http://stock.jrj.com.cn/2022/07/05222736785124.shtml",
    "datetime": "2022-07-05 22:27:53",
    "code": "688131"
  },
  {
    "title": "皓元医药(688131.SH)：真金投资已减持1.2491%的股份",
    "href": "http://stock.jrj.com.cn/2022/07/05222536785127.shtml",
    "datetime": "2022-07-05 22:25:21",
    "code": "688131"
  },
  {
    "title": "皓元医药：多股东拟合计减持不超9.5%公司股份",
    "href": "http://stock.jrj.com.cn/2022/06/20103436741824.shtml",
    "datetime": "2022-06-20 10:34:44",
    "code": "688131"
  },
  {
    "title": "皓元医药(688131)：持股5%以上股东减持股份计划",
    "href": "http://stock.jrj.com.cn/2022/06/20082236741215.shtml",
    "datetime": "2022-06-20 08:22:14",
    "code": "688131"
  },
  {
    "title": "皓元医药(688131.SH)：真金投资、景嘉创业等股东拟合计减持不超9.5%的股份",
    "href": "http://stock.jrj.com.cn/2022/06/19181036740702.shtml",
    "datetime": "2022-06-19 18:10:14",
    "code": "688131"
  },
  {
    "title": "皓元医药(688131)：2021年年度权益分派实施结果暨股份上市，每10股派发现金红利5.3元（含税）。",
    "href": "http://stock.jrj.com.cn/2022/06/11092136721270.shtml",
    "datetime": "2022-06-11 09:21:07",
    "code": "688131"
  },
  {
    "title": "“小额快速”重组！皓元医药拟4.1亿元购买药源药物100%股权，配套募资不超5000万元",
    "href": "http://stock.jrj.com.cn/2022/06/08102336711489.shtml",
    "datetime": "2022-06-08 10:23:08",
    "code": "688131"
  },
  {
    "title": "皓元医药（688131）：举行投资者关系活动",
    "href": "http://stock.jrj.com.cn/2022/06/08095636711380.shtml",
    "datetime": "2022-06-08 09:56:45",
    "code": "688131"
  },
  {
    "title": "皓元医药(688131)首次公开发行部分限售股于2022年6月8日上市流通",
    "href": "http://stock.jrj.com.cn/2022/05/31082636691728.shtml",
    "datetime": "2022-05-31 08:26:58",
    "code": "688131"
  },
  {
    "title": "皓元医药：约2706.30万股限售股将于6月8日解禁 占公司总股本比例36.4034%",
    "href": "http://stock.jrj.com.cn/2022/05/30185336690747.shtml",
    "datetime": "2022-05-30 18:53:56",
    "code": "688131"
  },
  {
    "title": "皓元医药(688131.SH)：2706.3038万股限售股将解禁",
    "href": "http://stock.jrj.com.cn/2022/05/30171936690033.shtml",
    "datetime": "2022-05-30 17:19:08",
    "code": "688131"
  },
  {
    "title": "皓元医药营收增长52.61% 不断加大自主技术创新和提升品牌能级建设双箭齐发",
    "href": "http://stock.jrj.com.cn/2022/05/23111036669555.shtml",
    "datetime": "2022-05-23 11:10:50",
    "code": "688131"
  },
  {
    "title": "皓元医药2022年第一季度净利6233.88万同比增长15.06% 管理效率和供应能力提升",
    "href": "http://stock.jrj.com.cn/2022/05/04113236554330.shtml",
    "datetime": "2022-05-04 11:32:55",
    "code": "688131"
  },
  {
    "title": "皓元医药披露2022年一季报 实现营收3.00亿元",
    "href": "http://stock.jrj.com.cn/2022/04/27104536482171.shtml",
    "datetime": "2022-04-27 10:45:53",
    "code": "688131"
  },
  {
    "title": "皓元医药(688131.SH)：一季度净利增15.06%至6233.88万元",
    "href": "http://stock.jrj.com.cn/2022/04/26205436478507.shtml",
    "datetime": "2022-04-26 20:54:07",
    "code": "688131"
  },
  {
    "title": "皓元医药2021年净利1.91亿同比增长48.7% 董事长郑保富薪酬71.85万",
    "href": "http://stock.jrj.com.cn/2022/04/22205136431611.shtml",
    "datetime": "2022-04-22 20:51:21",
    "code": "688131"
  },
  {
    "title": "皓元医药披露2021年年报 实现营收9.69亿元",
    "href": "http://stock.jrj.com.cn/2022/04/22093736426392.shtml",
    "datetime": "2022-04-22 09:37:28",
    "code": "688131"
  },
  {
    "title": "皓元医药(688131.SH)2021年度净利升48.70%至1.91亿元 拟10转4派5.3元",
    "href": "http://stock.jrj.com.cn/2022/04/22091436426279.shtml",
    "datetime": "2022-04-22 09:14:39",
    "code": "688131"
  },
  {
    "title": "皓元医药拟以不超4.2亿元收购药源药物100%股权，不构成重组上市",
    "href": "http://stock.jrj.com.cn/2022/03/07104034536821.shtml",
    "datetime": "2022-03-07 10:40:56",
    "code": "688131"
  },
  {
    "title": "皓元医药2021年净利1.91亿同比增长48.34% 本期订单量大幅增加",
    "href": "http://stock.jrj.com.cn/2022/02/24223134453541.shtml",
    "datetime": "2022-02-24 22:31:07",
    "code": "688131"
  },
  {
    "title": "皓元医药(688131.SH)：正筹划收购药源药物100%股权 2月21日起停牌",
    "href": "http://stock.jrj.com.cn/2022/02/18220734402336.shtml",
    "datetime": "2022-02-18 22:07:25",
    "code": "688131"
  },
  {
    "title": "皓元医药(688131.SH)：向221名激励对象授予80万股限制性股票",
    "href": "http://stock.jrj.com.cn/2022/02/15191034354857.shtml",
    "datetime": "2022-02-15 19:10:00",
    "code": "688131"
  },
  {
    "title": "皓元医药(688131.SH)：拟推2022年限制性股票激励计划",
    "href": "http://stock.jrj.com.cn/2022/01/26195234224812.shtml",
    "datetime": "2022-01-26 19:52:20",
    "code": "688131"
  },
  {
    "title": "皓元医药2021年预计净利1.8亿-1.99亿同比增长40%-55% 订单大幅增加",
    "href": "http://stock.jrj.com.cn/2022/01/24215134206712.shtml",
    "datetime": "2022-01-24 21:51:03",
    "code": "688131"
  },
  {
    "title": "皓元医药(688131.SH)2021年度净利润预增40%-55%",
    "href": "http://stock.jrj.com.cn/2022/01/24190134205801.shtml",
    "datetime": "2022-01-24 19:01:21",
    "code": "688131"
  },
  {
    "title": "皓元医药选举郑保富为董事长 第三季度公司净利4898.09万",
    "href": "http://stock.jrj.com.cn/2022/01/10220934143172.shtml",
    "datetime": "2022-01-10 22:09:16",
    "code": "688131"
  },
  {
    "title": "皓元医药(688131.SH)：选举郑保富为董事长",
    "href": "http://stock.jrj.com.cn/2022/01/10192134142462.shtml",
    "datetime": "2022-01-10 19:21:49",
    "code": "688131"
  },
  {
    "title": "皓元医药：公司目前不掌握卡龙酸酐批量生产工艺 也没有开发和量产此产品计划",
    "href": "http://stock.jrj.com.cn/2021/12/29134234080697.shtml",
    "datetime": "2021-12-29 13:42:36",
    "code": "688131"
  },
  {
    "title": "皓元医药(688131.SH)：75.99万股限售股将于12月8日解禁上市",
    "href": "http://stock.jrj.com.cn/2021/11/30194133945485.shtml",
    "datetime": "2021-11-30 19:41:56",
    "code": "688131"
  },
  {
    "title": "说明本次投资的合理性以及定价公允性？皓元医药这样回问询函",
    "href": "http://stock.jrj.com.cn/2021/11/03143433808025.shtml",
    "datetime": "2021-11-03 14:34:08",
    "code": "688131"
  },
  {
    "title": "自身变现能力一般 皓元医药仍1.44亿元收购资不抵债公司 收上交所问询函",
    "href": "http://stock.jrj.com.cn/2021/11/03083233807093.shtml",
    "datetime": "2021-11-03 08:32:00",
    "code": "688131"
  },
  {
    "title": "A股异动 | 皓元医药涨5% 拟以1.44亿元增资获得欧创基因90%股权",
    "href": "http://stock.jrj.com.cn/2021/10/27093833759602.shtml",
    "datetime": "2021-10-27 09:38:19",
    "code": "688131"
  },
  {
    "title": "皓元医药：拟1.44亿元增资获得欧创基因90%股权",
    "href": "http://stock.jrj.com.cn/2021/10/26203633756906.shtml",
    "datetime": "2021-10-26 20:36:29",
    "code": "688131"
  },
  {
    "title": "皓元医药(688131.SH)：第三季度净利增92.33%至4898.085万元",
    "href": "http://stock.jrj.com.cn/2021/10/26191733756347.shtml",
    "datetime": "2021-10-26 19:17:16",
    "code": "688131"
  },
  {
    "title": "皓元医药发业绩股价跌19% 半年净利不到1亿市值247亿",
    "href": "http://stock.jrj.com.cn/2021/08/26164833324769.shtml",
    "datetime": "2021-08-26 16:48:00",
    "code": "688131"
  },
  {
    "title": "皓元医药2021年半年度净利9500.02万元 同比净利增加110.23%",
    "href": "http://stock.jrj.com.cn/2021/08/25201433318528.shtml",
    "datetime": "2021-08-25 20:14:48",
    "code": "688131"
  },
  {
    "title": "皓元医药(688131.SH)：上半年净利增110.23%至9500.02万元",
    "href": "http://stock.jrj.com.cn/2021/08/25193233318247.shtml",
    "datetime": "2021-08-25 19:32:09",
    "code": "688131"
  },
  {
    "title": "皓元医药(688131.SH)：使用额度不超8亿元的暂时闲置募集资金进行现金管理",
    "href": "http://stock.jrj.com.cn/2021/07/13220233091221.shtml",
    "datetime": "2021-07-13 22:02:19",
    "code": "688131"
  },
  {
    "title": "皓元医药(688131.SH)：拟使用1.37亿元超募资金永久补充流动资金",
    "href": "http://stock.jrj.com.cn/2021/07/13220033091194.shtml",
    "datetime": "2021-07-13 22:00:33",
    "code": "688131"
  },
  {
    "title": "皓元医药(688131.SH)：拟向“安徽皓元”增资1.8亿元 以实施公司募投项目",
    "href": "http://stock.jrj.com.cn/2021/07/13214233091122.shtml",
    "datetime": "2021-07-13 21:42:57",
    "code": "688131"
  },
  {
    "title": "皓元医药：公司与国内生物药CDMO领域的领先企业上海臻格生物技术有限公司共同设立臻皓生物",
    "href": "http://stock.jrj.com.cn/2021/06/21100732967797.shtml",
    "datetime": "2021-06-21 10:07:35",
    "code": "688131"
  },
  {
    "title": "柘中股份(002346.SZ)：由苏信基金领投的首个投资项目皓元医药在科创板挂牌上市",
    "href": "http://stock.jrj.com.cn/2021/06/08202532895410.shtml",
    "datetime": "2021-06-08 20:25:44",
    "code": "688131"
  },
  {
    "title": "皓元医药首日涨382% IPO超募4.6亿民生证券赚0.77亿",
    "href": "http://stock.jrj.com.cn/2021/06/08151332893306.shtml",
    "datetime": "2021-06-08 15:13:00",
    "code": "688131"
  },
  {
    "title": "皓元医药：将于2021年6月8日在上海证券交易所科创板科创板上市",
    "href": "http://stock.jrj.com.cn/2021/06/06155132879764.shtml",
    "datetime": "2021-06-06 15:51:42",
    "code": "688131"
  },
  {
    "title": "皓元医药(688131.SH)：遭弃购5252股 由主承销商包销",
    "href": "http://stock.jrj.com.cn/2021/06/02194532865040.shtml",
    "datetime": "2021-06-02 19:45:34",
    "code": "688131"
  },
  {
    "title": "皓元医药(688131.SH)：回拨后网上发行最终中签率为0.02681650%",
    "href": "http://stock.jrj.com.cn/2021/05/30154232841035.shtml",
    "datetime": "2021-05-30 15:42:34",
    "code": "688131"
  },
  {
    "title": "今日申购：宏昌科技、皓元医药、凯立新材",
    "href": "http://stock.jrj.com.cn/2021/05/28090432833768.shtml",
    "datetime": "2021-05-28 09:04:00",
    "code": "688131"
  },
  {
    "title": "皓元医药(688131.SH)首次公开发行1860万股 发行价格64.99元/股",
    "href": "http://stock.jrj.com.cn/2021/05/26194032824780.shtml",
    "datetime": "2021-05-26 19:40:34",
    "code": "688131"
  },
  {
    "title": "皓元医药(688131.SH)：网上路演时间5月27日14:00-17:00",
    "href": "http://stock.jrj.com.cn/2021/05/25192532818023.shtml",
    "datetime": "2021-05-25 19:25:12",
    "code": "688131"
  },
  {
    "title": "皓元医药(688131)：首发1860万股 询价日期5月25日",
    "href": "http://stock.jrj.com.cn/2021/05/20105132786436.shtml",
    "datetime": "2021-05-20 10:51:29",
    "code": "688131"
  },
  {
    "title": "圣诺生物、皓元医药、科汇股份、博力威、和辉光电科创板IPO注册生效",
    "href": "http://stock.jrj.com.cn/2021/04/29092032477947.shtml",
    "datetime": "2021-04-29 09:20:19",
    "code": "688131"
  },
  {
    "title": "证监会同意圣诺生物、科汇股份、皓元医药、博力威科创板IPO注册",
    "href": "http://stock.jrj.com.cn/2021/04/27201732465222.shtml",
    "datetime": "2021-04-27 20:17:00",
    "code": "688131"
  },
  {
    "title": "皓元医药宣称研发人员333实为84人 销售费率畸高连续3年为行业均值三倍",
    "href": "http://stock.jrj.com.cn/ipo/2021/03/15071332229370.shtml",
    "datetime": "2021-03-15 07:13:31",
    "code": "688131"
  },
  {
    "title": "皓元医药宣称研发人员333实为84人 销售费率畸高连续3年为行业均值三倍",
    "href": "http://stock.jrj.com.cn/ipo/2021/03/15071332134491.shtml",
    "datetime": "2021-03-15 07:13:31",
    "code": "688131"
  },
  {
    "title": "皓元医药宣称研发人员333实为84人 销售费率畸高连续3年为行业均值三倍",
    "href": "http://stock.jrj.com.cn/ipo/2021/03/15071332336828.shtml",
    "datetime": "2021-03-15 07:13:31",
    "code": "688131"
  },
  {
    "title": "皓元医药宣称研发人员333实为84人 销售费率畸高连续3年为行业均值三倍",
    "href": "http://stock.jrj.com.cn/ipo/2021/03/15071332262313.shtml",
    "datetime": "2021-03-15 07:13:31",
    "code": "688131"
  },
  {
    "title": "此前行为是否会构成重大违法违规事项？皓元医药二次回复上市委意见落实函",
    "href": "http://stock.jrj.com.cn/2021/03/05112732077265.shtml",
    "datetime": "2021-03-05 11:27:18",
    "code": "688131"
  },
  {
    "title": "皓元医药科创板上市获批：业绩增长较快 存货跌价风险需留意",
    "href": "http://stock.jrj.com.cn/ipo/2021/01/19073431719291.shtml",
    "datetime": "2021-01-19 07:34:20",
    "code": "688131"
  },
  {
    "title": "皓元医药IPO过会：应收持续攀升 专利问题仍是焦点",
    "href": "http://stock.jrj.com.cn/ipo/2021/01/13081431680879.shtml",
    "datetime": "2021-01-13 08:14:05",
    "code": "688131"
  },
  {
    "title": "科创板IPO|终过会！皓元医药科创板IPO申请通过审核",
    "href": "http://stock.jrj.com.cn/2021/01/11171431670982.shtml",
    "datetime": "2021-01-11 17:14:07",
    "code": "688131"
  },
  {
    "title": "皓元医药过会：今年IPO过关第16家 民生证券过2单",
    "href": "http://stock.jrj.com.cn/2021/01/11100231668514.shtml",
    "datetime": "2021-01-11 10:02:00",
    "code": "688131"
  },
  {
    "title": "皓元医药1月8日科创板首发上会",
    "href": "http://stock.jrj.com.cn/2020/12/31204831614556.shtml",
    "datetime": "2020-12-31 20:48:00",
    "code": "688131"
  },
  {
    "title": "皓元医药成今年科创板暂缓审议第5家 民生证券折戟",
    "href": "http://stock.jrj.com.cn/2020/11/10102531249398.shtml",
    "datetime": "2020-11-10 10:25:00",
    "code": "688131"
  },
  {
    "title": "皓元医药、有研粉末11月9日科创板首发上会",
    "href": "http://stock.jrj.com.cn/2020/10/29171231158405.shtml",
    "datetime": "2020-10-29 17:12:00",
    "code": "688131"
  },
  {
    "title": "皓元医药冲刺科创板 核心专利和供应商缘何被质疑？",
    "href": "http://stock.jrj.com.cn/kcb/2020/07/27082830351455.shtml",
    "datetime": "2020-07-27 08:28:31",
    "code": "688131"
  },
  {
    "title": "皓元医药IPO：研发人员能力薪酬双低 技术服务采购费2年暴增12倍",
    "href": "http://stock.jrj.com.cn/2020/07/10173930206402.shtml",
    "datetime": "2020-07-10 17:39:10",
    "code": "688131"
  },
  {
    "title": "皓元医药2名实际控制人合计增持100万股",
    "href": "http://stock.jrj.com.cn/2017/12/19181423818304.shtml",
    "datetime": "2017-12-19 18:14:00",
    "code": "688131"
  }
]